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Purpose: To investigate deep reinforcement learning (DRL) based on historical treatment plans for
developing automated radiation adaptation protocols for nonsmall cell lung cancer (NSCLC) patients
that aim to maximize tumor local control at reduced rates of radiation pneumonitis grade 2 (RP2).
Methods: In a retrospective population of 114 NSCLC patients who received radiotherapy, a three-
component neural networks framework was developed for deep reinforcement learning (DRL) of
dose fractionation adaptation. Large-scale patient characteristics included clinical, genetic, and imag-
ing radiomics features in addition to tumor and lung dosimetric variables. First, a generative adversar-
ial network (GAN) was employed to learn patient population characteristics necessary for DRL
training from a relatively limited sample size. Second, a radiotherapy artificial environment (RAE)
was reconstructed by a deep neural network (DNN) utilizing both original and synthetic data (by
GAN) to estimate the transition probabilities for adaptation of personalized radiotherapy patients’
treatment courses. Third, a deep Q-network (DQN) was applied to the RAE for choosing the optimal
dose in a response-adapted treatment setting. This multicomponent reinforcement learning approach
was benchmarked against real clinical decisions that were applied in an adaptive dose escalation clin-
ical protocol. In which, 34 patients were treated based on avid PET signal in the tumor and con-
strained by a 17.2% normal tissue complication probability (NTCP) limit for RP2. The
uncomplicated cure probability (P+) was used as a baseline reward function in the DRL.
Results: Taking our adaptive dose escalation protocol as a blueprint for the proposed DRL
(GAN + RAE + DQN) architecture, we obtained an automated dose adaptation estimate for use at
 2/3 of the way into the radiotherapy treatment course. By letting the DQN component freely con-
trol the estimated adaptive dose per fraction (ranging from 1–5 Gy), the DRL automatically favored
dose escalation/de-escalation between 1.5 and 3.8 Gy, a range similar to that used in the clinical pro-
tocol. The same DQN yielded two patterns of dose escalation for the 34 test patients, but with differ-
ent reward variants. First, using the baseline P+ reward function, individual adaptive fraction doses
of the DQN had similar tendencies to the clinical data with an RMSE = 0.76 Gy; but adaptations
suggested by the DQN were generally lower in magnitude (less aggressive). Second, by adjusting the
P+ reward function with higher emphasis on mitigating local failure, better matching of doses
between the DQN and the clinical protocol was achieved with an RMSE = 0.5 Gy. Moreover, the
decisions selected by the DQN seemed to have better concordance with patients eventual outcomes.
In comparison, the traditional temporal difference (TD) algorithm for reinforcement learning yielded
an RMSE = 3.3 Gy due to numerical instabilities and lack of sufficient learning.
Conclusion: We demonstrated that automated dose adaptation by DRL is a feasible and a promising
approach for achieving similar results to those chosen by clinicians. The process may require cus-
tomization of the reward function if individual cases were to be considered. However, development
of this framework into a fully credible autonomous system for clinical decision support would require
further validation on larger multi-institutional datasets. © 2017 American Association of Physicists in
Medicine [https://doi.org/10.1002/mp.12625]
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1. INTRODUCTION
Most nonsmall cell lung cancer (NSCLC) patients are inoper-
able due to locally advanced disease or distant metastases and
thus radiation therapy (radiotherapy) becomes the main
option for treatment of these patients. However, treatment
outcomes remain relatively poor despite significant advances
in the technologies of radiotherapy planning, image-gui-
dance, and delivery.1 It is conjectured that escalation of radia-
tion dose is an option to improve treatment outcome results.
For instance, a dose increment by 1 Gy can lead to 1%
improvement in local progression free survival.2–3 However,
this has not always been demonstrated to be the case, as was
learned from RTOG-0617 clinical trial results, where dose
escalation has led to surprisingly negative results.4 Though
the specific causes of this negative finding are still being
worked out, it is clear that dose escalation cannot be
employed using a one-size-fits-all approach to the patient
population. While necessary for cancer treatment, radiother-
apy provides cure but can also pose risks that need to be tai-
lored according to each individual patients characteristics.
For treatment of lung cancer, a major limiting constraint to
dose escalation is the toxicity risk from thoracic irradiation
that leads to radiation-induced pneumonitis (RP). RP causes
cough, fever, etc, and it affects the quality of life for patients
even if the local control (LC) of the tumor is assured. There-
fore, an important question that the current studies are
attempting to address is: can machine learning algorithms
identify from patient characteristics an optimal dose schedule
to render LC with maximally reduced RP in an individual
patient? However, before attempting to address this challeng-
ing question, we need to demonstrate that machine learning
algorithms can actually be taught to mimic clinicians decision
making processes.
With the latest advances in machine reinforcement learn-
ing (RL) algorithms, which provide better dynamic learning
options, we are poised to explore the feasibility of automated
decision making for dose escalation in NSCLC patients. Tra-
ditional machine learning methods have witnessed increased
applications in radiotherapy including quality assurance,
computer-aided detection, image-guided radiotherapy, respi-
ratory motion management, and now outcomes prediction.5
However, traditional machine learning methods may lack the
ability to handle the dynamics of highly complex decision-
making process in a clinical radiotherapy environment. For
instance, our institutional protocol UMCC 2007-1232–3
defines dose escalation under a sophisticated adaptation pol-
icy (see Section 2.G.2) towards improved treatment out-
comes. Thus, it could be utilized as a suitable testbed to
assess our proposed RL methods for automated radiation
adaptation. The rationale for utilizing reinforcement learning
in automating radiation dose adaptation is that it allows
exploration of all possible paths into the future so that
expected benefits and risks can be weighed into the decision-
making process. In an analogous fashion such as playing
chess or board games, the decision maker needs to explore
the consequences of the next moves and develop an optimal
strategy to win the game, which in our case is controlling
cancer while reducing treatment side effects. To realize this
task within the complex radiotherapy environment, we devel-
oped dynamical procedures to utilize the existing historical
treatment plans to represent the radiotherapy environment
(Section 2.G.2), where the states within this environment are
defined as predictor factors of local control (LC) and radia-
tion-induced pneumonitis (RP) responses.
In recent years, deep learning applications have gained
success in variety of fields including video games, computer
vision, and pattern recognition. A key factor in this success
is that deep learning can abstract and extract high-level fea-
tures directly from the data. This helps avoid complex fea-
ture engineering or delicate feature hand-crafting and
selection for an individual task.6 Recent studies have
demonstrated that using a class of deep learning algorithms
based on convolution neural networks can efficiently replace
traditional feature selection in image segmentation. while at
the same time providing superior performance.7–8 These
strengths motivated Google DeepMind’s incorporation of
deep neural networks (DNN) into the known Q-learning
search algorithm of RL,9 which enabled it to master a
diverse range of Atari games with human-level performance
using the raw pixels and scores as inputs.10 The DQN algo-
rithm has been shown to display actions similar to human
instincts in playing these games. Such ability was demon-
strated by AlphaGo when it dethroned the world champion
of the ancient Chinese game GO, a 19 9 19 grid board
game considered to have intractable (316! ≃ 10678) possibili-
ties. The sheer complexity of GO renders the ability to make
human decisions from intuitive intelligence indispensable
for playing properly and having a credible chance at win-
ning. This study tends to pursue the characteristic of intu-
ition-driven decisions in the DQN for mimicking and
comparing clinicians dose adaptation decisions in treatment
planning. However, there are millions of records with
detailed moves of previously played games that could be
used in training the DQN algorithm; this is a luxury that we
do not possess in the clinical or the radiotherapy world.
Therefore, we also incorporated new developments in deep
learning for generating synthetic data to help meet the goal
of training automated actions owing to the demand of high-
sample-size requirement by the DQN. Specifically, we
deployed three different DNNs to tackle several problems in
building a machine learning approach for completing
automation of clinical decision-making for adaptive radio-
therapy, see Fig. 1(b). The first DNN (GAN, Section 2.E)
aims to generate sufficiently large patient data from existing
small-sized observations for training the simulated radiother-
apy environment. The second DNN is tasked to learn the
radiotherapy environment, i.e., where and how states would
transit under different actions (dose fraction modifications)
based on the data synthesized from the GAN and real clini-
cal data available, Section 2.G.3. The third DNN is the inno-
vative DQN itself responsible for prompt and accurate
evaluation of the different possible strategies (dose escala-
tion/de-escalation) and optimizing future rewards
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(radiotherapy outcomes). In contrast, classical RL methods
such as the model-free temporal difference (TD) algorithm,9
which require a sufficiently larger number of observations to
be sampled and high consistency in the states (variables)
and actions (decisions), do not fit well with the complex,
real clinical radiotherapy environment where the data are
noisy and complete information may be missing as well as
limited sample size. Moreover, clinical decisions are in gen-
eral likely to be more subjective than objective. These are
some of the hurdles that our approach based on the three-
component DNN design attempts to overcome. We believe
that the proper integration of these three components based
on deep learning is essential for building a robust RL envi-
ronment for decision support in radiotherapy adaptation.
In previous work,11 Kim et al. developed a Markov
decision process (MDP) from the perspective of analytical
radiobiological response to compute optimal fractionation
schemes in radiotherapy. The MDP design was based on
delicate assumptions on the latent behavior of the tumor
and the organs-at-risk (OAR) with respect to given dose.
Several numerical simulations were presented and their
behavior, based on the assumptions made, were discussed
but no realistic clinical scenarios were evaluated. Another
similar approach based on analyzing stochastic processes
of reinforcement learning with TD techniques12 was used
to dynamically explore the transition probability with
varying fractionation schedules. Based on simplified
radiobiological assumptions, different reward (utility)
functions were tested in preclinical cell culture data to
nonuniformally optimize the prescribed dose per
fraction.12
Here, implementation details and network architectures
are described and organized as follows. In Section 2, we suc-
cinctly introduce the methods and rationale of our utilization;
Section 3 demonstrates the results of the different compo-
nents of our proposed approach and their benchmarking
against real clinical protocol results. In Sections 4 and 5, we
summarize our methods presentation as an integrated system
and discuss future potential developments as well as the limi-
tations of our current study.
2. MATERIALS AND METHODS
2.A. Overview
In our investigation to apply DQN for escalation of dose
in NSCLC data, we first faced the obstacle of the absence of
a well-characterized radiotherapy environment (i.e., the rules
of the game) as shown in Figs. 1(a) and 4. This is unlike the
case of applying DQN to board games where complete infor-
mation of the game rules are defined beforehand and also one
can play the game repeatedly almost at no real cost. In the
case of patient care in general or radiotherapy specifically,
this would be ethically and practically prohibitive due to the
consideration of patients’ safety and the cost of time. To alle-
viate this difficulty, we developed a radiotherapy artificial
environment (RAE), also referred to as the (approximate)
transition DNN in Section 2.G.3 for simulating the radiother-
apy treatment response environment. Due to the limited avail-
able sample size, we combined the GAN with the transition
DNN to support the fidelity of reconstructing a RAE. As the
GAN can generate synthetic patient data very similar in its
characteristics to the real ones, we then trained the RAE with
mixed data; the synthesized data by the GAN and the avail-
able real clinical data. After the reconstruction of the radio-
therapy environment, we introduced the DQN agent (decision
maker) into this environment to interact with it, as indicated
in Fig. 1(b) and evaluated its performance by learning the
adaptive behavior of a dose escalation clinical protocol con-
ducted successfully in our institution and recently published
in JAMAOncology.3
2.B. Datasets
We used historical treatment plans of 114 NSCLC patients
for training our three-component DRL for decision support
of response-based dose adaptation. The patients had been
treated on prospective protocols under IRB approval as
described in Ref. [13] All tumor and lung dose values were
converted into their 2 Gy equivalents (EQD2) by an in-house
developed software using the linear-quadric model with an a/
b of 10 Gy and 4 Gy for the tumor and the lung, respectively.
How to let the DQN interact with
limited-sample-sized data of the historical patient
population treatment?
A 3-component DNN solution is proposed to (1) generate
synthetic data through GAN to (2) model the radiotherapy
environment by the transition DNN that is used by (3) the
DQN to make optimal decisions for adaptation of dose.
(a) (b)
FIG. 1. A three-component DNN solution to overcome limited sample size and model the radiotherapy environment for DRL decision-making.
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Generalized equivalent uniform doses (gEUDs) with various
parameters a were calculated for gross tumor volumes
(GTVs) and uninvolved lungs (lung volumes exclusive of
GTVs). Blood samples were obtained at baseline and after
approximately 1/3 and 2/3 of the scheduled radiation doses
were completed. A total of 250 features including dosimetric
variables, clinical factors, circulating microRNAs, single-
nucleotide polymorphisms (SNPs), circulating cytokines, and
positron emission tomography (PET) imaging radiomics fea-
tures before and during radiotherapy were collected. Pretreat-
ment blood samples were analyzed for cytokine levels, micro
RNAs (miRNAs), and single nucleotide polymorphisms
(SNPs), which have been identified as candidates from the lit-
erature as related to lung cancer response. FDG-PET/CT
images were acquired using clinical protocols and the pre-
treatment and intratreatment PET images were registered to
the treatment planning CT using rigid registration. The image
features analysis was performed using customized routines in
MATLAB and the features included metabolic tumor vol-
ume, intensity statistics, and texture-derived metrics.14,15 Part
of this population, with dose adaptations at  2/3 of the way
through treatment as served by Protocol UMCC 2007-123,2–3
are described in Section 2.G.1. Nine predictive features,
defined in Eq. (14) with characteristics described in Table I,
were selected for modeling the RAE. These features are
related to LC and RP2 responses based on Markov blankets
and Bayesian analyses as detailed in Ref. [13] and briefly
reviewed below.
2.C. Variable selection for simulating radiotherapy
environment
In order to define the radiotherapy environment via a
large-scale variable list, we used techniques based on Baye-
sian network graph theory, which allows for identifying the
hierarchical relationships among the variables and outcomes
of interest. The approach we used is based on identifying sep-
arate extended Markov blankets (MBs) for LC and RP2 from
the above high-dimensional dataset of 297 candidate vari-
ables. An MB of LC (or RP2) is the smallest set containing
all variables carrying information about LC (or RP2) that
cannot be obtained from any other variable (inner family);
then for each member in the blanket of LC (or RP2), a next-
of-kin MB for this member was also derived using a structure
learning optimization algorithm.13 The algorithm combines
efficient graph-search techniques with statistical resampling
for robust variable selection.13 The selected variables by this
approach are summarized in Eq. (14). It should be empha-
sized that the purpose of this step is to provide an approxi-
mate radiotherapy environment that would allow simulating
transitions between its states when the DQN agent is making
decisions.
2.D. Deep neural networks
We mainly utilized deep neural networks (DNNs) for our
proposed DRL approach and the main notations used are
summarized here for convenience. Denoting data {xi} with
labels {yi} such that X ¼ fðxi; yiÞjxi 2 Rn; yi 2 Rm
; i ¼ 1; . . .;Ng, a DNN finds a function fDNN : Rn ! Rm to
weave through the data such that fDNN(xi) ffi yi as much as
possible via the utility of three distinct components: neu-
ronszi 2 R, layers of k neurons z = (z1,. . .,zk), and activation
functions r, see Fig. 6 (left). If a DNN has layers j = 0,. . .,‘,
each of which has nj neurons, then j = 0 and ‘ would denote
the first (input) and final (output) layer, respectively. An acti-
vation function r : Rnj1 ! Rnj connecting the neurons of the
(j1)th layer zðj1Þ 2 Rnj1 and those of the jth layer zj 2 Rnj
would satisfy:
zðjÞ ¼ r Hðj1Þ  zðj1Þ þ bðj1Þ
 
(1)
where Hðj1Þ 2 Rnjnj1 and bðj1Þ 2 Rnj1 represent the
unknown weights and biases to be estimated. A typical choice
of r is a sigmoid or a rectified linear unit (ReLU), where we
empirically choose r = eLU 16 in this study for better conver-
gence. Our best parameters fHðjÞ; bðjÞg‘1j¼0 are then derived
TABLE I. Selected predictors for LC and RP2 and their characteristics.
Predictors Biological/clinical characteristics References
IL4 Th2 cytokines. Regulates antibody production, haematopoiesis, and inflammation. Promotes the differentiation
of naive helper T cells into Th2 cells. Decreases the production of Th1 cells
[26,27,28]
IL15 Th1 cytokines. Induces activation and cytotoxicity of natural kill (NK) cells. Activates macrophages.
Promotes proliferation and survival of T and B-lymphocytes and NK cells
[26,27,28]
GLSZM.GLN The gray-level nonuniformity (GLN) feature of a gray-level size zone matrix (GLSZM), defined
by
PNg
i¼1ð
PNr
j¼1 Pði; jÞÞ2=
PNg
i¼1
PNr
j¼1 Pði; jÞ:
Notations see Ref. [29]
GLRLM.RLN The run-length nonuniformity (RLN) feature of a gray-level run length matrix (GLRLM) defined
by
PNg
j¼1ð
PNr
i¼1 Pði; jÞÞ2=
PNg
j¼1
PNr
i¼1 Pði; jÞ:
Notations see Ref. [29]
MCP1 Chemokine expressed and secreted by adipocytes. Adipocyte expression of MCP-1 is increased by TNF-a [30,31]
TGFb1 Th2 cytokines. An important role in regulation of immune system. Produced by every leukocyte lineage,
including lymphocytes, macrophages, and dendritic cells
[32]
Lung/tumor gEUD
(a/b=4Gy,10Gy resp)
Generalized equivalent uniform dose of lung/tumor converted from EQD2 dose
distributions: EQD2 ¼ Nfrac  d  dþa=b2þa=b
  [33,34]
MTV Metabolic tumor volume from PET imaging –
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from the forward dynamics and backward (error) propagation
resulting from the DNN loss function:17
LðH;z;kÞ¼ 1
2
ky zð‘Þk2

X‘
j¼1
kðj1Þ;zðjÞ r Hðj1Þ  zðj1Þ þbðj1Þ
 D E
(2)
where kðj1Þ 2 Rnj1 are the Lagrange multipliers at layer
j  1 to preserve layerwise information Eq. (1).
In this study, we primarily rely on the universality of
DNNs to model the dynamic complexity hidden in the radio-
therapy data. This universality refers to the capability of a
neural network to approximate any continuous function (on a
compact subset of Rn) with suitable activation functions.18
Due to limited patient sample size, we implemented random
dropouts on neurons to efficiently mitigate overfitting19
throughout. In such scenario, randomly selected neurons are
assigned zero weights, which is a form of regularization to
prevent the network from overadaptation (overfitting) to the
data during training process.
2.E. Generative adversarial nets
To alleviate the problem of small sample size in clinical
datasets when modeling the complex state transitions in a
radiotherapy environment, we utilize generative adversarial
nets (GANs)20 to synthesize more radiotherapy patient-like
data. A GAN consists of two neural nets, one of which is gen-
erative (G) and responsible for generating synthetic data, and
the other one is discriminative (D), which tries to measure
the (dis)-similarity between the synthesized and real data as
shown in Fig. 2. The basic underlying idea is simple: by
learning to confuse D, G can get more sophisticated in gener-
ating similar data through the following setup.
Denote the space X  fx 2 Rng containing the (original)
dataset with distribution x  Pdata, and there is a latent
space Z ¼ fz 2 Rmg with a prior distribution z  Pprior,
where in our case a Gaussian distribution is assumed. The
generative network G : Z ! X tries to learn a map from Z
to X such that an induced probability distribution
PG ¼ PpriorðG1Þ  j detð@G1@x Þj on X is close to the original
Pdata. The discriminative network D : X ! R then simultane-
ously learns to discriminate observations from the true data
and the synthesized data generated by G. In general, G aims
at generating indistinguishable data to confuse D, whereas D
attempts to distinguish the data produced by G or not. They
interact with each other in a competitive sense, hence the
name GAN. The adversarial characters of D and G are cre-
ated via the loss function of two-player mini-max game:
min
G
max
D
LðD;GÞ ¼ min
G
max
D
ExPdataðxÞ logDðxÞ½ 
þ EzPpriorðzÞ logð1 DðGðzÞÞ½ ; (3)
where DðyÞ ¼
1; y is real
1=2 y is indistinguishable
0; y is generated
8<: .
Subsequently, we introduce the algorithm for generating
synthetic data for building our DRL for dose adaption.
2.F. Deep Q-networks
We are applying reinforcement learning to mimic how
physicians decide dynamically on the dose fraction trade-offs
needed to prescribe to a certain patient. In reinforcement
learning, there is the environment (an MDP) and an agent (an
optimal action search algorithm). An agent takes charge of
delivering actions a 2 A in an environment, which is a world
described by the various states s 2 S in the environment.
Upon a decision made under a current state p : S! A, an
agent receives corresponding reward R and gets promoted to
another state. The transition between states and rewards R are
feedback for the agent to perceive how to optimize its subse-
quent strategy for future actions. In our setting, an artificial
agent would provide a second opinion or take place of a
physician to deliver actions. Specifically, in this study, we
will evaluate the required dose per fraction (adaptation) in the
second period of a dose-escalation radiotherapy treatment
course. This agent will then interact with the radiotherapy
artificial environment (RAE) reconstructed by the transitional
FIG. 2. GAN is used to generate new data, where G asks D to verify the authenticity of the data source. From latent points z, generated patients are synthesized as ~x
in G. With y ¼ ðx; ~xÞ mixing with real and the generated patient data, D is trying to verify its source. [Color figure can be viewed at wileyonlinelibrary.com]
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DNN, Fig. 1(b), and adjust its own adaptation strategy based
on received feedback.
Reinforcement learning is essentially formulated as a Mar-
kov decision process (MDP), denoted by ðS;A;P; c;RÞ,
where S ¼ fðx1; . . .; xnÞ 2 Rng be the space of states, A is
the collection of actions, R : SA ! R is the reward func-
tion, and P : ðSA S;XÞ ! ½0; 1 is the transition proba-
bility function between two states under an action a 2 A with
Ω a r-algebra of SA S that naturally induces a condi-
tional probability PsaðtÞ 	 Probðtjs; aÞ 	 Pðs; a; tÞ=Pðs; aÞ
on space of next states t 2 S from previous observation
ðs; aÞ 2 SA. A sequence of actions acting on an initial
state s0 2 S leads to the dynamics of an MDP:
s0!a0 s1!a1 s2!a2    :
The Q-learning search algorithm is a common method to
find an optimal policy given an MDP or an RAE in our case,
where a Q-function is defined as the average discounted sum
of rewards R in all future steps from current state s under a
policy p : S! A as in Eq. (4). The expectation value is con-
sidered in the sense of computing all possible paths starting
from current states to represent all possible benefits received
in the future. A discounting factor 0 ≤ c ≤ 1 diminishes how
we perceive future profits, providing a trade-off between the
importance of immediate reward versus future ones, i.e.,
short-term responses versus long-term outcomes.
In Q-learning, an optimal policy p
 : S! A is defined
such that Qp

 ¼ maxp Qp is satisfied when the value iteration
scheme is adapted for computation. Via the Bellman’s equa-
tion of off-policy, the estimation of optimal Qp


is converted
into an iterative sequence f~Qig1i¼1 ! Qp


defined by9:
Qpðs; aÞ ¼ E
X1
k¼0
ckR sk; pðskÞð Þjp; s0 ¼ s; a0 ¼ a
" #
(4)
~Qiþ1ðs; aÞ ¼ EtPsa Rðs; aÞ þ cmaxb2A
~Qiðt; bÞ
 
: (5)
Upon the contraction mapping theorem,21 the convergence is
reached at the unique fixed point as i?∞,
~Q
ðs; aÞ ¼ EtPsa Rðs; aÞ þ cmaxb2A
~Q
ðt; bÞ
 
: (6)
It can be noticed that computation of Eq. (5) can quickly
become cumbersome when the cardinality |S| or jAj is large.
A recent solution proposed by Google DeepMind in Refs.
[10] and [22] was to evaluate the Q-function efficiently using
supervised learning by DNNs by ~Qi ¼ QHiDNN, where Hi
denotes the weights of DNNs in Eq. (1) at ith iteration with a
sequence of loss functions LiðHiÞ to be minimized where:
LiðHiÞ¼Eðs;aÞq
EtPsa Rðt;aÞþcmaxb2A Q
Hi1
DNNðt;bÞ
 
QHiDNNðs;aÞ
 2" #
:
(7)
where q is the probability distribution over policy sequences
s and actions a also called the behaviour distribution. The
loss function (7) can be understood to pursue a DNN
sequence fQHiDNNg1i¼1 such that

QHiDNN
	1
i¼1 ! fYig1i¼1 since
(7) indicates:
LiðHiÞ ¼ Eðs;aÞq Yiðs; aÞ  QHiDNNðs; aÞ
 2 
: (8)
by defining Yiðs; aÞ ¼ EtPsa ½Rðt; aÞ þ cmaxb2A QHi1DNNðt; bÞ
using QHi1DNNðs; aÞ at previous time t  1. It is also understood
that since one is not able to duplicate Yi exactly using a DNN
approximator QHiDNN at every iteration i due to the finite
degrees of freedom in DNN, namely (1), there always exists a
small error Yi  QHiDNN 6¼ 0 to be compensated by the loss
function (8), where Fig. 3 (left) shows their intertwined rela-
tionship. The sequence fYig1i¼1 approached by both opera-
tions of the DNN and the loss function (8) can be proven to
approximate the self-iterated sequence f~Qig1i¼1, whose con-
vergence to the optimal Q-function ~Q
 is already guaranteed
by the contraction mapping theorem. Summing up all the
facts one derives an operational sequence QHiDNN ! ~Q
 by
DNN as illustrated in Fig. 3 (right).
The reason a DNN approximator QHiDNN fails to play the
role ~Qi directly is because of the finite approximation ability
as mentioned above. Should a DNN have a perfect deforma-
tion such that Yi ¼ QHiDNN is true for all i, then
Yiðs; aÞ ¼ EtPsa ½Rðt; aÞ þ cmaxb2A Yi1ðt; bÞ, which leads
to the whole sequence fYig1i¼1 ¼ f~Qig1i¼1 by definition of (5).
In this perfect case, the three characters fYig1i¼1, f~Qig, and
fQHiDNNg1i¼1 coincide. Due to the imperfect nature of the DNN
approximator, the sequences fYig1i¼1, f~Qig, and fQHiDNNg1i¼1
split with tiny differences from one another. In fact, the
approximation accuracy of QHiDNN ! Yi can impact the perfor-
mance of a RL algorithm. A linear function approximator
was first considered in early literature23 for computational
reasons.
Besides using DNN for Q-function iteration, DQN also
utilizes techniques of experience replay memory and separat-
ing target networks to enhance its performance stability.22 As
mentioned in Section 2.A, since our DQN agent is not
allowed to explore optimal actions based on trial-and-error
(risky actions) in real patients, our approach towards deep RL
has to be different from common RL realizations used in non-
clinical applications. The autonomous actions will instead be
based on supervised learning from historical data rather than
direct online (or model-free) MDP learning as shown in
Fig. 4, which could complement previously learned actions.
First, we attempt to reconstruct the environment of radio-
therapy lung cancer patients from the existing data by an
approximate transition ~P! P of the real world. An accurate
reconstruction of the environment will require a large amount
of data to be available and reliable. This is why we utilized
GAN to synthesize patient-like data. After the reconstruction
of the radiotherapy artificial environment (RAE), we then
Medical Physics, 44 (12), December 2017
6695 Tseng et al.: Deep reinforcement learning for radiotherapy 6695
adopt deep Q-learning to search for the optimal policy
sequence for response-based dose adaptation.
2.G. Deep reinforcement learning for radiotherapy
dose adaptation
Before attempting to apply DRL for autonomous clini-
cal decision-making, a main purpose of this study was to
evaluate whether we can actually utilize reinforcement
learning to reproduce or mimic known clinical decisions
that have been previously made. To achieve this goal, we
design the following setup for dose adaptation of NSCLC
patients and test its performance using data from a suc-
cessful dose escalation protocol UMCC 2007-123.2–3 We
will first provide a brief description of this dose escalation
protocol, which will be used for benchmarking, followed
by the design of our proposed DRL system to mimic this
protocol.
2.G.1. Setting of protocol UMCC 2007-123
Protocol UMCC 2007-123 is a phase II dose escala-
tion clinical trial.3 The study aimed to demonstrate that
adaptive radiotherapy-escalated radiation dose to the
18F-fludeoxyglucose (FDG)-avid region detected by
midtreatment PET can improve local tumor control at
2 yr follow-up, with a reasonable rate of radiotherapy-
induced toxicity. In a population of 42 patients who had
inoperable or unresectable stage II to stage III NSCLC,
the trial demonstrated an 82% local control. The radia-
tion was delivered in 30 daily fractions of 2.1 to
5.0 Gy: 2.1 to 2.85 Gy fractions for the initial dose of
approximately 50 Gy EQD2, and 2.85 to 5.0 Gy for the
adaptive phase of treatments up to a total RT dose of
92 Gy EQD2.3 For the purpose of the DRL analysis,
we present the protocol succinctly as follows. A treat-
ment has total fractions f(t) and dose/fraction a(t) as
functions of time t with:
f ðt
Þ ¼ f0; f ðTÞ ¼ 30; aðtÞ ¼ a0; 0 t t
a1; t
  t T


(9)
where t* is the time for adaptation, T is the time of a complete
treatment with 0<t*<T and f0; a0; a1 are constants subject to
the conditions a0 2 ½2:1; 2:85 Gy, a1 2 ½2:85; 5 Gy, and the
total dose
63Gy a0f0 þ a1ð30 f0Þ 86Gy (10)
As mentioned above, the first 50 Gy (EQD2) of radiation will
be given based on pre-PET and pre-CT, the remaining dose is
delivered to the target based on avid mid-treatment FDG-PET
uptake as identified by the metabolic tumor volume (MTV).
The protocol requires NTCP of lung to be maintained
≤ 17.2% (approximately equivalent to 20 Gy mean lung
dose) based on estimates by the LKB model:24
NTCPðxÞ ¼ 1ffiffiffiffiffi
2p
p
Z x
1
e
u2
2 du (11)
with
x ¼ lung gEUD  TD50
m  TD50 : (12)
The clinical endpoint for lung NTCP in the protocol
UMCC 2007-123 was RP2. The dataset of NSCLC has:
a0 ffi 2; a1 2; f0 ffi 20; T ¼ 6weeks;
t
 ffi week 4 ¼ 23 treatment
(13)
as shown in Fig. 5. We designed our agent to adapt dose after
week 4 of the treatment, i.e., to find the best policy for a1 of
Eq. (9) after t = t*.
2.G.2. Setting for deep reinforcement learning
In DRL, one needs to decide the representation of states,
where in our case the states should contain enough patients
information to indicate or reflect changes in possible treat-
ment outcomes. In reality, there are numerous variables
including hidden ones that may be related to radiotherapy
treatment outcomes; it is not feasible to choose all of them.
Hence, to develop the transition probabilities, we selected
nine variables related to cytokines, SNPs, miRNA, and PET
radiomics features in order to predict LC and RP2 (see
Table I) by using the Bayesian network approach developed
in Ref. [13] to represent the RAE states. Hence, to develop
the transition probabilities, we selected important variables to
represent the RAE states for LC and RP2 prediction (see
FIG. 3. Machinery of DQN convergence. The left figure depicts the relation between {Yi} and fQHiDNNg, where arrow “⇒” denotes “create” and “” denotes “ap-
proximate”. The right figure illustrates the convergence relationship between three sequences.
FIG. 4. An incomplete MDP where the environment is unknown or missing.
[Color figure can be viewed at wileyonlinelibrary.com]
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Table I) based on our previous Bayesian network analysis13
as follows. Firstly, constraint-based local discovery algo-
rithms using Markov blankets were employed to select the
variables that are mostly related to LC or RP2 from the high
dimensional dataset (297 candidate variables). Then we built
a single Bayesian network from these selected variables for
both LC and RP2 prediction by using graph learning algo-
rithms (score-based learning algorithm and leaf node elimi-
nation) with statistical resampling by bootstrapping to
mitigate overfitting. Finally, the nodes in the BN with the
highest AUC value for joint prediction of LC and RP2 were
determined and evaluated using cross-validation. This pro-
cess resulted in nine selected features, which included cytoki-
nes, SNPs, miRNA, and PET radiomics features that were
considered important predictors to represent the state
variables.
In this study, we are interested in determining how much
dose should be delivered according to patients’ information
and thus compute an optimal policy of dose/fraction to
mimic/compare with known clinical decisions based on dose
adaptation protocols as benchmark for evaluation. This leads
us to define the reward (15), as a trade-off between encourag-
ing improved LC and attempting to suppress RP2. The last
term here is meant to comply with the clinical protocol
requirement for the probability of RP2 risk not to exceed
17.2%.
Definition Define the state variables s ¼ ðx1; . . .; xnÞ 2 S
with n = 9,
x1¼ IL4 x2¼ IL15; x3¼GLSZM:GLN;
x4¼GLRLM:RLN;
x5¼MCP1; x6¼ TGFb1; x7¼ LunggEUD;
x8¼ TumorgEUD; x9¼MTV
(14)
where x1, x2, x5, x6, x9 are cytokines, x3, x4 are of PET radio-
mics, and x7, x8 are dose features. Let A ¼ fa1 ¼ dose=fracg
 Rþ be the allowed actions after t = t* and define our
reward function R(s,a) = R(s) based on the complication-free
tumor control (P+) utility25 while respecting the dose escala-
tion clinical protocol requirement:
RðsÞ ¼ 1
2
ProbðLCjsÞ  1 ProbðRP2jsÞ  1
þ sgnð17:2% ProbðRP2jsÞÞ

;
sgnðxÞ ¼
1; x[ 0
0; x ¼ 0
1; x\0
8<:
(15)
where s 2 S, Prob(LC|s) is the conditional probability of
obtaining tumor local control after observing state s, similar
for Prob(RP2|s).
In the computational aspect of DQN, the Q-function in
Eq. (7) is defined to have a similar form to (4) but with a
DNN structure and weights Θ that could be tuned for better
approximation of the real Q-function:
QHDNN : S! RjAj by QHDNNðsÞ ¼
Qðs; a1Þ
Qðs; a2Þ
..
.
Qðs; akÞ
0BBB@
1CCCA (16)
where the inputs and the outputs are adjusted in order to take
advantage of deep learning capabilities rather than literally
follow (4). We remark that at each state s, another two DNN
classifiers were trained for predicting prob (LC|s) and prob
(RP2|s) for more accurate computation of the reward (15).
Since accurate evaluation of LC and RP2 is also considered
as part of the natural transition of the environment that
requires as much precision as possible, another two classi-
fiers based on the selected 9 predictors were built to predict
the LC and RP2 probabilities trained using the clinical out-
comes rather than only the approximation by the LKB model
(11). An episode is a sequence of states performed by an
FIG. 5. An approximated environment reconstructed from data to simulate radiotherapy adaptation response of patients. A DQN agent manages to extract infor-
mation from the data of the right-hand side based on the two transitions (blue-dashed and red-solid arrows, explained in Eq. (17) later) and submit actions at the
2/3 period of a treatment (right solid-green arrow), where the environment is hidden in this illustration. At the end of a whole treatment course, the complete
information is then collected for reconstructing the radiotherapy environment (dashed-green arrow). [Color figure can be viewed at wileyonlinelibrary.com]
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agent according to a developed policy p. The termination of
an episode was set to invoke whenever Prob(LC|s) > 70%
and Prob(RP2|s) < 17.2% are attained.
2.G.3. Setting for probability transition function and
building the radiotherapy artificial environment
(RAE)
The reconstruction of the RAE then relies on a well-
approximated transition function from the dataset. For this
purpose, our data of NSCLC of N = 114 patients are orga-
nized in the following form,
sð0Þi jsð1Þi jsð2Þi
h i
¼ week 0jweek 2jweek 4½ ;
að0Þi jað1Þi
h i
¼ week 0 7!week 2jweek 2 7!week 4½ :
where sðkÞi ¼ ðxðkÞi1 ; xðkÞi2 ; . . .; xðkÞin Þ 2 S denotes the ith patient at
the kth period of treatment with n predictors, i = 1,. . .,N.
k = 0 denotes the period of the treatment t = 0week 2;
k = 1 is t = week 2week 4 and k = 2 stands for t = week
4week 6. In full expansion, the data corresponding to
Fig. 5 has the form of table with 3 blocks:
An approximate transition probability trained by a DNN
~P : S A S! ½0; 1 indicates the probability transforming
from an old state s to a new states t under action a:
~Pðs; a; tÞ :¼ ~PsaðtÞ :¼ gProbðtjs; aÞ. The training was per-
formed by state transitions from different patients and two
time periods (pre- and during radiotherapy) (k = 0,1) with a
total sample size of twice the size of the patients.
~P
sðkÞi ;a
ðkÞ
i
sðkþ1Þi
 
¼ gProb sðkþ1Þi jsðkÞi ; aðkÞi  (18)
with fyi ¼ sðkþ1Þi g served as labels in the loss function
L ¼
X1
k¼0
XN
i¼1
jjyDNN sðkÞi ; aðkÞi
 
 yjj2 (19)
where yDNN is a set of DNN classifiers to simulate ~P. In our
pilot DNN simulations, we observed that the range of state
variables has large variations from one another and a single
network architecture did not provide satisfying predictions.
Thus, to achieve better approximation, we employed n = 9
sets of independent DNNs, denoted by DNN1,DNN2,. . .,
DNN9, to predict the i
th variable with its own DNNi such that
the ensemble prediction of all variables would yield
yDNN ¼ ðyDNN11 ; yDNN22 ; . . .; yDNN99 Þ. By doing this, we were
able to calculate the corresponding probabilities of next pos-
sible states gProbðtjs; aÞ as the product of each separate vari-
able’s transition probability.
Furthermore, to increase the credibility of the Q-function
evaluation based upon the Bellman’s iteration (5), we
searched up to Npossible = 100 next possible transitions via
top probabilities of yDNN to distribute possible Q-values visu-
alized in Fig. 6 (right) where each layer displays the 100 most
possible moves under any given action. For comparison with
board games, it worth noting that in chess, the possible num-
ber of moves is around 20 for the average position while in
GO it is about 200.
Although the Bayesian network may provide some con-
straints on the state transitions, for the majority in our fully
connected neural network, there is no obvious causal relation-
ship between state variables xi that could be proven. There-
fore, we only considered independent DNNs instead of
recurrent neural network approaches.35 Our design of the
transition function is shown in Fig. 6.
2.G.4. Setting for generative adversarial network
(GAN)
To generate necessary patient sample size for the training
of the transition probability function, we chose a feature
space containing 3 periods of a treatment plan altogether:
X ¼ sð0Þ; að0Þjsð1Þ; að1Þjsð2Þ
 
2 R3nþ2
n o
and define a prior latent space Z ¼ fz 2 Rm¼10g equipped
with multivariate normal distribution zNðl;RÞ where
l = 0 and Σ = 0.05I are used. With the completed settings
of GAN + transition DNN + DQN, our framework for lung
dose adaptation is depicted by Fig. 5.
3. EXPERIMENTS AND RESULTS
3.A. Model architecture and computational
performance
Each DNN of yiDNN, i = 1,. . .,9 in yDNN contains two hid-
den layers with exponential linear unit (eLU) activations16
and softmax for output layer such that the topology resulted
in [n,60,60,nlevels], where nlevels denotes the number of cate-
gory variables being discretized. Particularly, we took
nlevels = 3 since according to Ref. [13] the best prediction
falls within range xi 2 f1; 0; 1g denoting the low, mid, or
high value of a given predictor. All DNNs were trained with
random dropouts in neurons to avoid overfitting pitfalls. The
DNN of the DQN QHDNN is equipped with two hidden layers
in eLU activation functions with topology ½n; 120; 120; jAj.
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Training operations for the DNNs under the described struc-
ture utilized the ADAM optimizer, which is a first-order gra-
dient-based optimization of stochastic objective functions
using adaptive estimates of lower-order moments.36 In our
case, the GAN training took roughly 7,000 epochs with two
batches for generating synthetic data; the transition DNN
training took 35,000 iterations and the DQN learning ran
30,000–50,000 iterations. Our deep learning algorithms are
based on Tensorflow.37 All experiments were implemented in
ARC-TS high-performance computer cluster (FLUX) with 6
NVIDIA K40 GPUs.
3.B. Results
3.B.1. Generated adversarial network
With the setting of Section 2.G.4, 4,000 new patients
were synthesized based on the original data by GAN,
which attempts to infer the probability distribution of
patients characteristics from limited sample size. As an
unsupervised learning method, we measured the GAN per-
formance using the loss function (3) and analyzed the data
similarity between the original clinical data and the gener-
ated ones as shown in the histograms of Fig. 7. The
results show good agreement between our original and
synthesized patients characteristics based on the selected
nine variables.
3.B.2. The transition probability function of
radiotherapy artificial environment
With the generated patient data provided by GAN, the
transition probability function of nine discretized chosen vari-
ables could be trained more reliably. We predicted each vari-
able interaction independently as mentioned in Section 2.G.3
such that an ensemble DNN classifier would represent the
radiotherapy artificial environment yiDNN with its inputs and
outputs given by:
yiDNN : f1; 0; 1g9 ! f1; 0; 1g (20)
where the cross-entropy loss function of multiclass prediction
was adopted for training:
LðHÞ ¼  1
N
XN
i¼1
XK
k¼1
yðkÞi log r
ðkÞðH  z‘1i Þ
 
(21)
Using a total sample size of 4,114 with 35,000 iterations for
each batch, the following average accuracy for each predictor
on 10-fold cross-validation was obtained as shown in Fig. 8
ranging from 0.55–1.0.
3.B.3. DQN optimal dose per fraction prediction
For reinforcement learning being neither a pure super-
vised nor a unsupervised learning method, accurate evalua-
tion of an agent can be quite challenging.10,38 Following,39
our metric for the DQN agent measures the total rewards
collected in each episode (a complete treatment course).
Figure 9(a) illustrates the total rewards in 10,000 episodes
by our in-house DQN on a classical game MountainCar for
instance, where a well-defined environment is provided by
OpenAI40 for training RL agents. It is observed that most
of RL algorithms demonstrate oscillating behavior includ-
ing DQN, where the RL learner here is demonstrated to be
stable and accurate in deriving the rewards. On the other
hand, Fig. 9(b) evaluates the total reward of automated
dose adaptation collected in 10,000 episodes, which are rel-
atively noisy due to the higher complexity of the radiother-
apy environment and the associated uncertainties within
several components: the GAN error, the transition probabil-
ity function, and the joint LC-RP2 classifier and also the
oscillating behavior of the DQN itself.
FIG. 6. Random dropout DNNs (left) are used with data (z(0),z(l)) = (x,y) following notations in Sec. IID to reconstruct the transition probability of the environ-
ment (right), where ~Psa : ðx1; x2; . . .; x9Þ7!ðy1; y2; . . .; y9Þ is an approximation to the real world. Different layers are consequences of different actions made on
the state (x1,x2,. . .,x9). At each layer, 100 possible status of a patient are considered according to top transition probabilities. This process repeats itself at every
state of each layer. [Color figure can be viewed at wileyonlinelibrary.com]
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Dose fraction prediction results are shown in Fig. 10,
where the autonomous actions a1 of a(t) in Eq. (9) are com-
puted towards achieving optimal rewards (15) by the DQN to
maximize LC rate while minimizing RP2 probability. We
allowed the agent to freely control dose from a1 ¼ 1 5Gy
such that A ¼ f1; 1:1; 1:2; . . .; 5g Gy are permissible. The
DQN algorithm was evaluated on 34 patients from the institu-
tional dose escalation study (UMCC Protocol 2007-123) who
had complete information on the nine selected variables of
the RAE. Qualitatively, it is noted that the DQN automati-
cally favored doses between 1.5 and 3.8 Gy, which coincides
with the original decision support range of the clinical proto-
col. This shows the ability of the DQN to learn the effective
support interval for treatment adaptation according to the
clinical protocols as shown in Fig. 10. Quantitatively, the esti-
mated root-mean-square error (RMSE) ≃0.76 Gy, which sug-
gests good agreement with clinical decisions but still has
relatively high errors for practical considerations.
However, it was also noted that the DQN decisions based
on Eq. (15) were consistently lower than their clinical coun-
terparts. Notably, a manual translation by about 0.75 Gy to
all automated dose can achieve a better agreement in RMSE.
Besides using a manual constant shift, a natural way to better
mimicking the clinical actions is to appropriately modify the
reward function by emphasizing higher local control beyond
the baseline P+ function as follows:
RðsÞ ¼ 1
2
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ProbðLCjsÞ
p
 1 w  ProbðRP2jsÞ  1
þ sgnð17:2% ProbðRP2jsÞÞ

;
(22)
with w = 0.8. This reward function mainly increases the
weight on LC due to
ffiffi
x
p  x; 8x 2 ½0; 1 with RP2 weighting
FIG. 7. Each subfigure demonstrates approximate probability distribution of a predictor xi, i = 19 by its histogram. Blue-shaded areas represent the distribu-
tions of the original data, while the green-shaded areas represent the distributions of the generated data by GAN. [Color figure can be viewed at wileyonlinelibrar-
y.com]
FIG. 8. The mean accuracy of each predictor: (y1,y2,. . .,
y9) = (0.88,0.65,0.93,1.00,0.55,0.99,0.83,0.98,0.49) with an error bar visual-
ized. [Color figure can be viewed at wileyonlinelibrary.com]
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remained unchanged. As a result, most of doses were esca-
lated to achieve higher LC rate as shown in Fig. 11 achieving
an RMSE = 0.5 Gy. Moreover, by considering the knowl-
edge of final outcomes of treatments, we would be able to
compare the decisions made by the DQN and those by the
clinicians. Under the guiding principle of “doing no harm”,
our evaluation criteria is defined in Table III. Using coloring
dots in green and red as indications of “good” and “bad”
respectively in Fig. 11, one may identify the quality of the
decisions made. As a result, this criteria suggest that the clini-
cian made 19 good and 15 bad decisions, whereas that DQN
had 17 good, 4 bad, and 13 potentially good decisions, as
organized in Table II. The results show that there is no signif-
icant difference between the clinicians and the DQN in the
category of “good” while there exist differences in the cate-
gory of “bad” and “potentially good”, which may favor the
DQN in such uncertain situations. Particularly, this “poten-
tially good” category shown in orange dots of Fig. 11 with
(LC, RP2)=(+,) and reduced dose computed by DQN
seems to lower the adaptive dose for decreasing risky
situations, which could be partly related to the fact that the
actual outcomes were used in training the LC/RP2 predictors.
However, this would require further independent validation.
The decisions of the DQN versus the clinicians in Fig. 11
can also be summarized in the boxplots of Fig. 12. The data
in the plots were analyzed using two-tailed Wilcoxon signed-
rank test of paired differences in medians at 5% level of
significance.41 For the nonadaptive cases, there was no signif-
icant difference between the clinical decisions and the DQN’s
(P-value = 0.83). However, in the case of adapted patients
there was a difference (P-value = 0.001). Using one-tailed
analysis it is noted that DQN decisions were generally lower
(more conservative) than the clinicians’ with P-value
= 0.0006.
3.B.4. Comparison with temporal difference method
We also compared our proposed approach based on DQN
to the traditional RL methods based on TD(0), which is a
model-free approach.9 Among the different TD(k)
FIG. 9. Total rewards of episodes collected by the DQN in two different tasks, where a classical game MountainCar is compared with the artificial environment
reconstructed for the dose adaptation. [Color figure can be viewed at wileyonlinelibrary.com]
FIG. 10. Automated dose decisions given by DQN (green dots) vs. clinical decision (blue dots) with RMSE 0.76 Gy. [Color figure can be viewed at wileyonline-
library.com]
Medical Physics, 44 (12), December 2017
6701 Tseng et al.: Deep reinforcement learning for radiotherapy 6701
techniques, 0 ≤ k ≤ 1, the TD(0) without eligibility trace
used is the closest counterpart to DQN and therefore was cho-
sen for this comparison. The results of TD(0) shown in
Fig. 13 are far off from the clinical decisions
(RMSE = 3.3 Gy ) in comparison to the DQN suggestions
which may be due to the lack of numerical stability in the
Q-value computation. Specifically, this could be attributed to
the fact that traditional TD is designed for navigating limited
known discrete states in the environment and learn the under-
lying environment model, whereas the DQN can still deter-
mine a possible action even if a state was not previously
observed as in the large radiotherapy state space S defined in
Eq. (14). Moreover, the generated RAE in our case and inher-
ent replay memory device of DQN contribute to improving
the RL stability and convergence, which is not the case in tra-
ditional RL.
4. DISCUSSION
In this study, we have explored the feasibility of develop-
ing a deep reinforcement learning (DRL) framework for
dynamic clinical decision making in adaptive radiotherapy.
Reinforcement learning as a different category of machine
learning, besides typical supervised and unsupervised learn-
ing, has its own prerequisites. A major portion of its develop-
ment relies on having a well-defined environment
ðS;A;P; c;RÞ of a Markov Decision Process (MDP), which is
a challenge to construct in the case of a complex radiotherapy
process with its clinical settings, known experimental con-
straints, and also limited available datasets to explore such an
environment. Therefore, we devised a modified DQN archi-
tecture which is neither model-free nor model-based, as
strictly speaking such approaches would indicate an ability to
learn the transition state behavior dynamically during consec-
utive observations and actions made (e.g., board games),
which is not permissible here with the large number of the
states and the limited data available. In order to approximate
~P! P to be sufficiently reliable, the corresponding data for
reconstruction must be adequate and usable for training. This
FIG. 11. Automated dose decisions given by DQN (black solid line) vs. clinical decision (blue dashed line) with RMSE = 0.5 Gy. An evaluation of good (green
dots), bad (red dots), and potentially good decisions (orange dots) are labeled according to Table III. [Color figure can be viewed at wileyonlinelibrary.com]
TABLE II. Summary for the evaluation on clinicians’ and the DQN decisions.
Summary Good Bad Potentially good
clinicians 19 (55.9%) 15 (44.1%) 0
DQN 17 (50%) 4 (11.8%) 13 (38.2%)
TABLE III. Evaluation of automated dose adaptation, where relative dose 	
(automated dose  clinical given dose). It should be noted that the notion of
good or bad here is quite subjective. For instance, if a patient eventually
obtains RP2 without LC, but the DQN suggested higher than the clinical
dose given, this is considered as a bad decision. See the row with LC = ,
RP2 = + and relative dose > 0.
LC label RP2 label Evaluation for clinicians
+  Good
+ + Bad
 + Bad
  Bad
LC label RP2 label Relative dose Evaluation for DQN
  ≤ 0 Bad
  > 0.2 Good
 + ≥ 0.2 Bad
 + < 0.2 Good
+  = 0 Good
+  > 0 Bad
+  < 0 Potentially good
+ + ≥ 0 Bad
+ + < 0 Good
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problem was tackled in this work by using the GAN
approach, which allowed us to generate new synthetic
data with characteristics resembling the original limited
observations.
In the dataset containing NSCLC of 114 patients who
received radiotherapy as part of their treatment and had suffi-
cient (clinical, dosimetric, and biological) information to
model RAE, automated dose adaptation by DRL was evalu-
ated on a subset (34 patients) who underwent an institutional
dose-adaptive escalation protocol (UMCC 2007-123). Our
DNNs utilized only two hidden layers, which are developed
for our RL application and the corresponding data type,
although they are relatively shallower than the Microsoft’s
Residual Nets or the Google’s Inception Net, for instance,
especially tasked for image recognition of large dataset. How-
ever, more layers (abstraction levels) may be needed as
our adaptive radiotherapy datasets grow in terms of variables
(-omics) and sample size.
The reward function in the current work was selected
based on prior knowledge and empirical experiences to
mimic the clinical adaptation scenario, since the real reward
in clinical practice may not be accessible or known. We ini-
tially used the reward (15) to derive the suggested dose using
the known P+ based utility function and RP2 constraint to
FIG. 12. The comparison on 34 patients of protocol 2007-123 divided into groups with and without adaptation. FX1 denotes the dose/frac given in the first 2/3
period of the treatment; clinical denotes that of the last 1/3 treatment based on protocol 2007-123 compared with the DQN results using modified reward (20).
Note that some patients in FX1 on the left figure were given maximum dose 2.85 Gy/frac according to protocol in Section 2.G.1. [Color figure can be viewed at
wileyonlinelibrary.com]
FIG. 13. Automated dose decisions given by TD(0) method (green dots) vs. clinical decision (blue dots) with RMSE ≃ 3.3 Gy. Possible reasons for the TD
method failure to mimic the clinical decisions is the convergence instability. [Color figure can be viewed at wileyonlinelibrary.com]
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mimic the original protocol, which resulted in an RMSE
around 0.76 Gy as shown in Fig. 10. However, this reward
function resulted in consistent underestimation of the sug-
gested dose (too conservative), and therefore we adjusted the
reward function to attain closer policies pDQN : S! A from
the same agent. As suggested by Eq. (20), this adjusted
reward function provided higher weights on increasing local
control (i.e., raising dose to attain higher LC rates) as shown
in Fig. 11. Other possible reward functions are discussed in
Ref. [12]. The demonstration of how changing rewards would
lead to different policies was shown in Figs. 10 and 11.
Besides utilizing empirical knowledge to define the reward
functions used here, an alternative approach called inverse
reinforcement learning (IRL) can be applied to reverse engi-
neer the reward hidden inside the real world based on a per-
fect mentor,42 which may not be available in practical clinical
settings and would be considered as a subject of future work.
Interestingly, we noticed in our results that the DRL not
only achieved comparable results to clinical decisions but
also can make recommendations that would help adjust cur-
rent decisions as part of its training when used as a second
reader decision support system. The current study has
focused on mimicking clinical decisions as a proof-of-princi-
ple and as validation of the feasibility of DRL for automated
dose adaptation applications. However, this algorithm would
require further validation on independent datasets once they
become available. The use of Bayesian networks as shown
here could help constrain the environment as well as define
the reward functions. The Bayesian networks not only help
predict outcomes but also identify hierarchical relationships
within the state variables, which is currently being
investigated.
Another limitation of this study is that we only considered
a single adaptation action of changing the dose/fraction rather
than, for instance, devising a continuous adaptation protocol
on a daily or weekly basis. However, this is due to the nature
of action information availability within our current data. If
one could retrieve more data of tumor response or status
monitoring closely/continuously during treatment, this would
provide more time stamps to build a more accurate model of
RAE and eventually help in reducing the DQN learning error.
The information used to reconstruct the RAE environment
was limited to certain molecular biomarkers and PET imag-
ing data. However, this information could be further enriched
by utilizing tumor and normal tissue response and monitoring
indicators from radiogenomics43 or noninvasive new imaging
information from CT radiomics,44 advanced ultrasound,45–47
magnetic resonance spectroscopy,48 or optical imaging in the
case of superficial tumors.49 Should more data become avail-
able, continuous adaptive decision-making may be intro-
duced and further evaluated using the proposed DRL
approach.
5. CONCLUSIONS
Our study introduced deep RL as a viable solution for
response-adaptive clinical decision making. We proposed a
combination of three deep learning components: GAN +
transition DNN + DQN to provide an automated dose adap-
tation framework as shown in Fig. 1(b). All three components
are essential and complementary to each other- from generat-
ing the necessary training data for learning the transition
probability of the approximated environment to searching for
the optimal actions. The use of deep Q-networks as a modern
reinforcement learning technique allows us to potentially
realize automated decision making in complex clinical envi-
ronments such as radiotherapy. Towards this goal, we approx-
imated the transition probability function from historical
treatment plans via independent DNNs and GAN to generate
sufficient synthetic patient data for training. Our proposed
method was demonstrated successfully on an institutional
dose escalation study with empirical reward functions. How-
ever, further developments and validations on larger multi-
institutional datasets are still required for building an autono-
mous clinical decision support system for response-based
adaptive radiotherapy.
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